Lung Cancer Considered

By IASLCScience

Lung Cancer Considered episodes

April 24 LCC in Spanish: Manejo perioperatorio en cáncer de pulmón en estadio temprano
This episode of Lung Cancer Considered, part of IASLC’s World Language Series, features host Dr. Narjust Florez leading a Spanish-language discussion with Dr. José Corona-Cruz and Dr. Diego Carrillo on perioperative chemoimmunotherapy in early-stage lung cancer. Using a real-world case, they explore clinical decision-making, biomarker considerations, and surgical challenges, with a focus on implementation barriers in Latin America. The conversation highlights multidisciplinary strategies and practical insights to optimize care in resource-variable settings.
49 min
April 21 IASLC - Nursing & Allied Health in Lung Cancer Care and Clinical Research
This episode of LCC covers the work of our nursing and allied health professional committee and, most importantly, highlight their role in the care of patients with thoracic malignancies.
Guests:
Professor Nicole Kiss is a Fellow of Dietitians Australia and Clinical Associate Professor in the Institute for Physical Activity and Nutrition at Deakin University. Nicole co-leads the Exercise and Nutrition for Cancer research group, with her research focused on early identification of cancer-related muscle loss and improving access to treatment.
Dr. Morten Quist is a former IASLC Board member and is currently an Associate Professor and Research Physiotherapist at the University Hospital of Copenhagen, Rigshospitalet. For the past 25 years, he has pioneered clinical exercise-based rehabilitation for people living with cancer, with a primary focus on exercise, prehabilitation, and rehabilitation in lung cancer. His work bridges research, clinical care, patient advocacy, and voluntary engagement – always with patient wellbeing at the center.
49 min
April 07 IASLC - Lung Cancer Considered India
This episode of Lung Cancer Considered covers lung cancer in India and brings awareness about its first and largest advocacy group in the nation. To learn more about Lung Connect India, key members of the team will share how the organization began and the work they have done to improve the care of patients with lung cancer in the region.
Guest:
Vandana Mahajan, Lead Counselor for Lung Connect India, brings a unique and inspiring voice shaped by her dedication to supporting patients and families affected by lung cancer, and her commitment to driving conversations that matter from prevention and early detection to treatment advances and survivorship.
Sanjeev Sharma, the Director & CEO of Lung Connect India, an initiative dedicated to improving awareness, access, and advocacy in lung cancer care. With a strong commitment to patient-centered innovation, he works to bridge gaps between patients, caregivers, clinicians, and policymakers, advancing meaningful dialogue and practical solutions to improve lung cancer outcomes
43 min
April 03 LCC in Korean: A Case-Based Discussion on EGFR-Mutant NSCLC
As part of IASLC’s ongoing podcast series in world languages, Dr. Chul Kim moderates a discussion in Korean with Dr. Beung-Chul Ahn and Dr. Hyein Jeon. The session focuses on the clinical management of EGFR-mutant non-small cell lung cancer (NSCLC) through a case-based discussion.
Guests:
34 min
March 20 IASLC LCC - Early Stage and Preoperative Care for NSCLC and EFGR in Mandarin
In this episode, recorded in Mandarin, host Dr. Chunxia Su leads a discussion about early stage and preoperative care for patients with NSCLC with an EGFR mutation.
Guests:
Wenzhao Zhong, Deputy Prensendent of Guangdong Provincial People's Hospital, Director of the Cancer Institute, Guangdong Provincial People's Hospital
Jie Hu， Deputy director, Department of Respiratory Medicine, Shanghai Geriatric Medical Center，Zhongshan Hospital, Fudan University
Min Fan M D， Deputy Director , Department of Radiation Oncology, Fudan University Shanghai Cancer Center
49 min
March 17 IASLC - TTLC_Molecular Tumor Board
In this episode of Lung Cancer Considered, host Dr. Narjust Florez conducts three mock molecular tumor boards with Dr. Misako Nagasaka and Dr. Biagio Ricciuti, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion addresses the question, “How do we get the right molecular answer, at the right time, for the right patient?”
Guests:
Misako Nagasaka, MD, PhD
Associate Clinical Professor
University of California, Irvine
Biagio Ricciuti, MD, PhD
Thoracic Medical Oncologist, Dana-Farber Cancer Institute
Faculty, Harvard School of Medicine
55 min
March 10 Live from TTLC 2026: ADCs Controversies
In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guest Dr. Sam Rosner examine controversies around antibody-drug conjugates (ADCs) live from the 2026 Targeted Therapies of Lung Cancer (TTLC) conference.
Guest:
Sam Rosner, MD
Assistant Professor of Medicine, University of Maryland School of Medicine
Thoracic Medical Oncologist, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
39 min
March 06 LCC in French_Virtual Tumor Board - EFGR NSCLC (1)
As part of IASLC’s ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Angela Botticella and Dr. Jean Yannis Perentes. The tumor board focuses on the management of resectable EGFR-mutant NSCLC.
Guests:
Angela Botticella, MD
Radiational Oncologist
Department of Radiation Oncology
Gustave Roussy
Jean Yannis Perentes, MD, PhD
Professor and Chief, Department of Thoracic Surgery
University Hospital of Lausanne CHUV
44 min
March 03 Virtual Tumor Board: EGFR-mutant NSCLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by Dr. Sara Pilotto and Dr. Jonathan Riess for a virtual tumor board discussion on the management of metastatic EGFR exon 19 NSCLC . Using a complex case featuring discordant biomarker results and brain metastases, the panel explores first-line treatment strategies including osimertinib monotherapy, FLAURA2 (osimertinib plus chemotherapy), and MARIPOSA (amivantamab plus lazertinib), as well as sequencing at progression, re-biopsy, CNS considerations, and the evolving role of local consolidation and clinical trials.
48 min
February 27 Controversies in the Management of Lung Cancer: Comorbidities
In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores controversies in managing lung cancer patients with comorbidities – those often underrepresented in clinical trials – with Dr. Hina Khan and Dr. Corey Langer, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion examines treatment decision-making in patients with ECOG performance status 2, renal dysfunction, advanced age, and complex comorbid conditions, emphasizing careful phenotyping, geriatric assessment, and individualized risk–benefit evaluation. The episode also highlights the balance between efficacy, toxicity, quality of life, and patient goals when treating the patients most commonly seen in clinical practice.
Guests:
Hina Khan, MD
Thoracic Oncologist
Assistant Professor of Medicine
Warren Alpert Medical School, Brown University
Corey Langer, MD, FACP
Director, Thoracic Oncology, Abramson Cancer Center
Professor of Medicine , Perelman School of Medicine
University of Pennsylvania
49 min

About Lung Cancer Considered

From the publisher's feed

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.